SAM
BBIO icon

Smartleaf Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Smartleaf Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8K Hold
595
– – ﹤0.01% 1600
2026
Q1 		$41.3K Sell
595
-144
-19% -$10.4K ﹤0.01% 1554
2025
Q4 		$55.8K Buy
739
+286
+63% +$18.8K ﹤0.01% 1492
2025
Q3 		$23.5K Buy
453
+262
+137% +$12.8K ﹤0.01% 1745
2025
Q2 		$8.57K Sell
191
-164
-46% -$5.96K ﹤0.01% 1876
2025
Q1 		$12.5K Buy
355
+98
+38% +$3.3K ﹤0.01% 1841
2024
Q4 		$7.02K Buy
257
+25
+11% +$646 ﹤0.01% 2131
2024
Q3 		$5.79K Buy
232
+179
+338% +$4.7K ﹤0.01% 2055
2024
Q2 		$1.33K Buy
+53
New +$1.45K ﹤0.01% 2346

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Smartleaf Asset Management's BBIO Position: Q2 2026 in Review

Smartleaf Asset Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 595 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Smartleaf Asset Management first reported a position in BBIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $55.8K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Smartleaf Asset Management held 595 shares of BridgeBio Pharma worth $42.8K as of Q2 2026.
  • Smartleaf Asset Management left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1600 holding.
  • Smartleaf Asset Management first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's BridgeBio Pharma position peaked at $55.8K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.